Administering DNase can currently be achieved through aerosols, and some clinical trials (NCT04359654, NCT04402970, NCT04541979, NCT04445285) have tested inhaled DNase1 administration in severe COVID-19 patients, with some benefits reported [38]. The gene discussed is DNASE1; the disease is COVID-19.